Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 8.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron (REGN 1.33%) has been ... No doubt the drugmaker owes this performance in part to its coronavirus-related work. However, ... 1 Dividend Stock Down 30% to Buy and Hold for the Next Decade.

No doubt the drugmaker owes this performance in part to its coronavirus-r. Skip to main content. Nasdaq+. Weekly ... Is Regeneron Stock a Buy Now? March 11, 2022 — 11:30 am EST.

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

REGEN-COV sales, as discussed, will fall from $5.8bn in FY21 to just $681.2m in FY22, but the performance of both Libtayo ... IMO LT investors should continue to buy REGN’s stock every 3-months.

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago ...

And that's why I'm taking a close look at Regeneron Pharmaceuticals (REGN-0.75%), which is trading at about $830 after touching a recent peak of $847.50. Could this big biotech company be next to ...